← Back to Search

Lifestyle Interventions for Obesity (PIVOT Trial)

N/A
Recruiting
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 50 - 74 years (inclusive)
Diagnosis of 1 or more cardiometabolic condition (prediabetes, metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia) in the EHR
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Awards & highlights

Summary

This trial will investigate how a lifestyle program and coaching can help middle-aged adults reduce their risk for chronic disease by improving their weight. Results may help to tailor the program for personalized care.

Who is the study for?
Adults aged 50-74 with a BMI ≥27 and diagnosed with conditions like high blood pressure, dyslipidemia, or type 2 diabetes can join. They must be willing to use digital tools for monitoring and have Wi-Fi at home. Exclusions include active weight loss treatment, substance abuse disorders, serious health issues like recent heart attack or cancer treatment.
What is being tested?
The PIVOT Trial is testing if a video-based lifestyle program improves weight and reduces chronic disease risk in older adults when enhanced by remote coaching. It explores personal success factors and integrates the program into patients' electronic health records for easy access at home.
What are the potential side effects?
Since this trial involves lifestyle changes rather than medication, side effects are not typical as with drug trials. However, participants may experience discomfort adjusting to new diet or exercise routines.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 74 years old.
Select...
I have been diagnosed with a condition like prediabetes, high blood pressure, or high cholesterol.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess change in weight from baseline to 52 weeks post randomization
Secondary study objectives
Assess changes in cardiovascular risk at 52 weeks
Assess changes in cognitive functioning at 6, 12, 24 and 52 weeks
Assess changes in efficacy in diet change at 6, 12, 24 and 52 weeks
+14 more

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Group E: Augmented Intervention (Non-responders)Experimental Treatment1 Intervention
Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52.
Group II: Group D: Base Intervention (Non-responders)Experimental Treatment1 Intervention
Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
Group III: Group C: Base Intervention (Responders)Experimental Treatment1 Intervention
Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
Group IV: Group A: Waitlist-Base InterventionActive Control1 Intervention
Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52.
Group V: Group B: Waitlist-Augmented InterventionActive Control1 Intervention
Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Base intervention
2019
N/A
~70

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
632 Previous Clinical Trials
1,566,686 Total Patients Enrolled
University of PittsburghOTHER
1,762 Previous Clinical Trials
16,346,974 Total Patients Enrolled
Washington University School of MedicineOTHER
1,970 Previous Clinical Trials
2,307,594 Total Patients Enrolled

Media Library

Augmented Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05654142 — N/A
Cardiometabolic Conditions Research Study Groups: Group E: Augmented Intervention (Non-responders), Group A: Waitlist-Base Intervention, Group C: Base Intervention (Responders), Group B: Waitlist-Augmented Intervention, Group D: Base Intervention (Non-responders)
Cardiometabolic Conditions Clinical Trial 2023: Augmented Intervention Highlights & Side Effects. Trial Name: NCT05654142 — N/A
Augmented Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05654142 — N/A
Cardiometabolic Conditions Patient Testimony for trial: Trial Name: NCT05654142 — N/A
~612 spots leftby Oct 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top